Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Allergic Conjunctivitis
Interventions
DRUG

RX-10045

RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.

DRUG

Vehicle for RX-10045 arm

Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.

Trial Locations (1)

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

C.T. Development America, Inc.

INDUSTRY

NCT01639846 - Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter